A Multicenter, Randomized, Double-blinded, Parallel, Positive-controlled, Phase III Comparative Study to Evaluate GS101 Injection Versus Dupixent® in Participants With Moderate-to-Severe Atopic Dermatitis
Latest Information Update: 09 Feb 2026
At a glance
- Drugs Dupilumab (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Sponsors Jiangsu Genscend Biopharma
Most Recent Events
- 09 Feb 2026 New trial record